Medics for Rare Disease launches campaign highlighting the “five-year wait” faced by patients with rare diseases Medics for Rare Disease has launched a new awareness campaign highlighting the significant impact of delayed diagnosis in rare disease, with touchNEUROLOGY proud to ...

ESOC 2026 highlights: Blood pressure management, neuroprotection and widening inequalities shape stroke discussions in Maastricht #VoiceOfStroke [caption id="attachment_101685" align="alignright" width="300"] © European Stroke Organisation #VoiceOfStroke[/caption] At the 12th European Stroke Organisation Conference 2026, late-breaking clinical trial data and population-level analyses ...

Kathy Costello, CMSC, and Bonnie Blain, IOMS, join together to discuss four decades of innovation in MS, from MRI and DMTs, to emerging neuroprotective strategies and personalized care.   As the Consortium of Multiple Sclerosis Centers (CMSC) celebrates its 40th ...

New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...

Prof. Peter Hedera discusses the potential of tiomolibdate choline to improve neurologic outcomes and reduce deterioration risk in Wilson disease. Neurologic worsening remains one of the greatest treatment challenges in Wilson disease, where delayed diagnosis and paradoxical deterioration during therapy ...

Findings from the HOPE-3 phase 3 trial demonstrate positive effects on upper limb function and cardiac outcomes in Duchenne muscular dystrophy New phase 3 data presented at the American Academy of Neurology Annual Meeting 2026 highlight the potential of deramiocel as a novel ...

New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...

New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment ...

Dr Micah Luftig discusses the implications for clinical risk stratification and early intervention, and how EBV-targeted strategies may shape future therapeutic approaches Growing evidence has positioned Epstein–Barr virus (EBV) as a central factor in the development of multiple sclerosis (...